Maze Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MAZE research report →
Range $64 – $64
Price Chart
About the company
Maze Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
- CEO
- Jason Coloma
- IPO
- 2025
- Employees
- 141
- HQ
- South San Francisco, CA, US
Get TickerSpark's AI analysis on MAZE
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.47B
- P/E
- -9.66
- PEG
- 0.18
- P/S
- 73.28
- P/B
- 3.45
- EV/EBITDA
- -10.16
- Div Yield
- 0.00%
- Gross Margin
- 95.28%
- Op Margin
- -728.06%
- Net Margin
- -667.95%
- ROE
- -34.94%
- ROIC
- -28.35%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-2,403,000-101.4%
- Op Income
- $-142,899,000
- Net Income
- $-131,120,000-351.0%
- EPS
- $-3.05-4020.3%
- OCF Growth
- -247.4%
- FCF Growth
- -250.7%
- 52W High
- $53.65
- 52W Low
- $21.95
- 50D MA
- $26.98
- 200D MA
- $32.92
- Beta
- 2.15
- RSI (14)
- 51
- Avg Volume
- 563.69K
No earnings-call transcripts are available for MAZE yet.
- Free Float
- 28.9%
- Shares Outstanding
- 55.35M
- Float Shares
- 15.98M
of shares held by institutions
176 13F filers
Buy/sell ratio 0.25. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 5.03M | ▲ 465.64K |
| Trv Gp Iv, LLC | 4.47M | 0 |
| Arch Venture Management, LLC | 4.12M | 0 |
| Deep Track Capital, LP | 3.73M | ▲ 255.01K |
| Blackrock, Inc. | 3.50M | ▲ 932.42K |
| Jupiter Topco LLC | 3.41M | ▲ 3.41M |
| Janus Henderson Group Ltd. | 2.86M | ▼ 283.71K |
| T. Rowe Price Investment Management, Inc. | 2.60M | ▲ 2.60M |
| Logos Global Management LP | 1.94M | ▲ 700.00K |
| Vanguard Capital Management LLC | 1.78M | ▲ 342.57K |
| Ah Capital Management, L.L.C. | 1.70M | 0 |
| Vanguard Group Inc | 1.70M | ▲ 362.06K |
Held by 198 ETFs
Biggest fund positions in MAZE by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | Coloma Jason V | sell | 31,908 |
| Oct 1, 26 | Coloma Jason V | sell | 2,593 |
| Oct 1, 26 | Bernstein Harold | other | 16,141 |
| Oct 1, 26 | Bernstein Harold | other | 16,141 |
| Oct 1, 26 | Bernstein Harold | sell | 16,141 |
| Sep 29, 26 | Dandekar Atul | other | 7,500 |
| Sep 29, 26 | Dandekar Atul | sell | 7,500 |
| Sep 29, 26 | Dandekar Atul | other | 7,500 |
| Sep 4, 26 | Bernstein Harold | sell | 9,705 |
| Sep 2, 26 | Courtney Phillips | sell | 1,738 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MAZE coverage
Recent articles, reports, and earnings notes.
No research on MAZE yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MAZE report →3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlight
marketbeat.com · Oct 5
Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40
defenseworld.net · Oct 1
Maze Therapeutics (NASDAQ:MAZE) Shares Climb 4.5% – Still a Buy?
defenseworld.net · Sep 30
Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up – Time to Buy?
defenseworld.net · Sep 24
Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000
fool.com · Sep 11
Maze Therapeutics, Inc. (MAZE) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
seekingalpha.com · Sep 10
Maze Therapeutics, Inc. $MAZE is Frazier Life Sciences Management L.P.’s 8th Largest Position
defenseworld.net · Sep 7
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
globenewswire.com · Sep 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.